154 related articles for article (PubMed ID: 16398403)
61. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
62. Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Kern JA; Herndon JE; Tatum A; Brisson ML; Memoli V; Sugarbaker D; Skarin AT; Kreisman H; Green MR
Lung Cancer; 1998 Sep; 21(3):203-11. PubMed ID: 9857998
[TBL] [Abstract][Full Text] [Related]
63. Neuroendocrine differentiation in renal cell carcinoma--evaluation of chromogranin A and neuron-specific enolase.
Rasmuson T; Grankvist K; Roos G; Ljungberg B
Acta Oncol; 1999; 38(5):623-8. PubMed ID: 10427952
[TBL] [Abstract][Full Text] [Related]
64. Differences of molecular expression mechanisms among neural cell adhesion molecule 1, synaptophysin, and chromogranin A in lung cancer cells.
Kashiwagi K; Ishii J; Sakaeda M; Arimasu Y; Shimoyamada H; Sato H; Miyata C; Kamma H; Aoki I; Yazawa T
Pathol Int; 2012 Apr; 62(4):232-45. PubMed ID: 22449227
[TBL] [Abstract][Full Text] [Related]
65. The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer.
Gajra A; Tatum AH; Newman N; Gamble GP; Lichtenstein S; Rooney MT; Graziano SL
Lung Cancer; 2002 May; 36(2):159-65. PubMed ID: 11955650
[TBL] [Abstract][Full Text] [Related]
66. A retrospective analysis of serum tumor markers found in non-small cell lung cancer.
Hu Q; Xiao P; Li J; Yu P
J Cancer Res Ther; 2016; 12(1):117-20. PubMed ID: 27072222
[TBL] [Abstract][Full Text] [Related]
67. Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients.
Wu JT; Astill ME; Liu GH; Stephenson RA
J Clin Lab Anal; 1998; 12(1):20-5. PubMed ID: 9484665
[TBL] [Abstract][Full Text] [Related]
68. Pretreatment Levels of Chromogranin A and Neuron-specific Enolase in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia.
Kečkéš Š; Palaj J; Waczulíková I; Dyttert D; Mojtová E; Kováč G; Durdík Š
In Vivo; 2021; 35(5):2863-2868. PubMed ID: 34410979
[TBL] [Abstract][Full Text] [Related]
69. Prognostic significance of the aberrant expression of neuroendocrine markers in melanomas.
Wu Y; Lai Y; Zhang M; Li Z
Diagn Pathol; 2021 Aug; 16(1):78. PubMed ID: 34454530
[TBL] [Abstract][Full Text] [Related]
70. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
Dong B; Fan L; Wang Y; Chi C; Ma X; Wang R; Cai W; Shao X; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Kang X; Zhou L; Xue W
Prostate; 2017 May; 77(13):1373-1380. PubMed ID: 28804908
[TBL] [Abstract][Full Text] [Related]
71. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer.
Graziano SL; Mazid R; Newman N; Tatum A; Oler A; Mortimer JA; Gullo JJ; DiFino SM; Scalzo AJ
J Clin Oncol; 1989 Oct; 7(10):1398-406. PubMed ID: 2550590
[TBL] [Abstract][Full Text] [Related]
72. Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer.
Chang KT; Huang CY; Tsai CM; Chiu CH; Lok YY
Am J Physiol Lung Cell Mol Physiol; 2005 Sep; 289(3):L438-45. PubMed ID: 15894559
[TBL] [Abstract][Full Text] [Related]
73. Correlation between chromogranin A, neuron-specific enolase and synaptophysin expression, and some clinico-pathological features of colorectal cancer.
Famulski W; Sulkowska M; Miller-Famulska D; Kisielewski W; Sulkowski S
Folia Histochem Cytobiol; 2001; 39(2):155-6. PubMed ID: 11374802
[TBL] [Abstract][Full Text] [Related]
74. Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications.
Segawa Y; Takata S; Fujii M; Oze I; Fujiwara Y; Kato Y; Ogino A; Komori E; Sawada S; Yamashita M; Nishimura R; Teramoto N; Takashima S
J Cancer Res Clin Oncol; 2009 Aug; 135(8):1055-9. PubMed ID: 19152002
[TBL] [Abstract][Full Text] [Related]
75. Reliability of commercially available immunocytochemical markers for identification of neuroendocrine differentiation in bronchoscopic biopsies of bronchial carcinoma.
Gosney JR; Gosney MA; Lye M; Butt SA
Thorax; 1995 Feb; 50(2):116-20. PubMed ID: 7701447
[TBL] [Abstract][Full Text] [Related]
76. Circulating neuroendocrine markers in patients with prostate carcinoma.
Berruti A; Dogliotti L; Mosca A; Bellina M; Mari M; Torta M; Tarabuzzi R; Bollito E; Fontana D; Angeli A
Cancer; 2000 Jun; 88(11):2590-7. PubMed ID: 10861438
[TBL] [Abstract][Full Text] [Related]
77. [Clinical significance of serum neuron-specific enolase in non-small cell lung cancer].
Kimura H; Yamaguchi T; Nishino K; Nakagawa M; Yokota S; Nishikawa H; Ito M; Ogura T
Nihon Kokyuki Gakkai Zasshi; 1998 Feb; 36(2):128-32. PubMed ID: 9617138
[TBL] [Abstract][Full Text] [Related]
78. Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A.
Lai M; Lü B; Xing X; Xu E; Ren G; Huang Q
Virchows Arch; 2006 Oct; 449(4):402-9. PubMed ID: 16955307
[TBL] [Abstract][Full Text] [Related]
79. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.
Iizasa T; Fujisawa T; Saitoh Y; Hiroshima K; Ohwada H
Cancer Immunol Immunother; 1998 Aug; 46(6):345-9. PubMed ID: 9756419
[TBL] [Abstract][Full Text] [Related]
80. Evaluation of chromogranin A expression in patients with non-neuroendocrine tumours.
Tropea F; Baldari S; Restifo G; Fiorillo MT; Surace P; Herberg A
Clin Drug Investig; 2006; 26(12):715-22. PubMed ID: 17274678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
